Compounds > imatinib
Page last updated: 2024-08-16

imatinib and cgp 53716

imatinib has been researched along with cgp 53716 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Böhmer, FD; Elz, S; Eswayah, A; Mahboobi, S; Sellmer, A; Uecker, A1
Hao, X; Ji, L; Li, X; Lü, S; Luo, Q; Wang, F; Zheng, W1
Chen, SP; Cui, J; Fu, R; Li, GW; Liu, S; Qian, SX; Zhou, LH1

Other Studies

3 other study(ies) available for imatinib and cgp 53716

ArticleYear
Inhibition of PDGFR tyrosine kinase activity by a series of novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides: a SAR study on the bioisosterism of pyrimidine and imidazole.
    European journal of medicinal chemistry, 2008, Volume: 43, Issue:7

    Topics: Imidazoles; Magnetic Resonance Spectroscopy; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship

2008
Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors.
    Bioorganic & medicinal chemistry letters, 2011, Dec-01, Volume: 21, Issue:23

    Topics: Benzamides; Crystallography, X-Ray; Enzyme Activation; Hydrogen Bonding; Imatinib Mesylate; Mass Spectrometry; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines

2011
BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives.
    Bioorganic & medicinal chemistry letters, 2013, Apr-15, Volume: 23, Issue:8

    Topics: Drug Design; Fusion Proteins, bcr-abl; Models, Molecular; Protein Kinase Inhibitors; Pyrimidines; Quantitative Structure-Activity Relationship

2013